BELVIN MARCIA 4
4 · CytomX Therapeutics, Inc. · Filed Jun 17, 2025
Insider Transaction Report
Form 4
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-06-13+37,500→ 286,136 total - Sale
Common Stock
2025-06-16$2.69/sh−13,884$37,334→ 272,252 total - Exercise/Conversion
Performance Stock Units
2025-06-13−37,500→ 0 total→ Common Stock (37,500 underlying)
Footnotes (4)
- [F1]This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
- [F2]Includes 158,958 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
- [F4]Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.